Jane Street Group, LLC Fibrogen Inc Put Options Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 17, 2022	SELL	$12.02 - $16.79 $10,818 - $15,111	-900 Reduced 5.77%	14,700 $177,000
Q4 2021 Feb 15, 2022	SELL	$9.93 - $15.39 $146,964 - $227,772	-14,800 Reduced 48.68%	15,600 $220,000
Q3 2021 Nov 16, 2021	SELL	$10.18 - $26.64 $4.47 Million - $11.7 Million	-438,800 Reduced 93.52%	30,400 $311,000
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $8.43 Million - $16.2 Million	454,200 Added 3028.0%	469,200 $12.5 Million
Q1 2021 May 18, 2021	BUY	$31.0 - $55.72 $27,900 - $50,148	900 Added 6.38%	15,000 $521,000
Q4 2020 Feb 17, 2021	BUY	$37.09 - $48.97 $66,762 - $88,146	1,800 Added 14.63%	14,100 $523,000
Q3 2020 Nov 17, 2020	SELL	$40.47 - $45.5 $942,951 - $1.06 Million	-23,300 Reduced 65.45%	12,300 $506,000
Q2 2020 Aug 17, 2020	SELL	$32.57 - $42.83 $159,593 - $209,867	-4,900 Reduced 12.1%	35,600 $1.44 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $1.4 Million - $1.95 Million	40,500 New	40,500 $1.74 Million
Q2 2018 Aug 15, 2018	SELL	$44.9 - $64.95 $435,530 - $630,015	-9,700 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $439,895 - $598,005	9,700 New	9,700 $448,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.